DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.
VEGF-targeted therapy increases both the progression-free (PFS) and overall survival (OS) of patients with metastasized renal cell cancer (mRCC). Identification of molecular phenotypes of RCC could improve risk-stratification and the prediction of the clinical disease course. We investigated whether...
| Κύριοι συγγραφείς: | , , , , , , , , , , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
Public Library of Science (PLoS)
2014-01-01
|
| Σειρά: | PLoS ONE |
| Διαθέσιμο Online: | http://europepmc.org/articles/PMC3954691?pdf=render |